Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 5;73(7):e2243-e2250.
doi: 10.1093/cid/ciaa1531.

Infectious Diseases/Human Immunodeficiency Virus Physician Ambassadors: Advancing Policy to Improve Health

Maximo O Brito  1   2 , Caitlin M Dugdale  3   4 , Michelle Collins-Ogle  5 , Jessica Snowden  6 , David A Wheeler  7   8
Affiliations

Infectious Diseases/Human Immunodeficiency Virus Physician Ambassadors: Advancing Policy to Improve Health

Maximo O Brito et al. Clin Infect Dis. .

Abstract

Infectious diseases/human immunodeficiency virus (ID/HIV) physicians and other healthcare professionals advocate within the healthcare system to ensure adults and children receive effective treatment. These advocacy skills can be used to inform domestic and global infectious diseases policies to improve healthcare systems and public health. ID/HIV physicians have a unique frontline perspective to share with federal policymakers regarding how programs and policies benefit patients and public health. Providing this input is critical to the enactment of legislation that will maximize the response to infectious diseases. This article discusses the advocacy of ID/HIV physicians and other healthcare professionals in federal health policy. Key issues include funding for ID/HIV programs; the protection of public health and access to healthcare; improving research opportunities; and advancing the field of ID/HIV, including supporting the next generation of ID/HIV clinicians. The article also describes best practices for advocacy and provides case studies illustrating the impact of ID/HIV physician advocacy.

Keywords: HIV; infectious diseases; physician advocacy.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Earnest MA, Wong SL, Federico SG. Perspective: physician advocacy: what is it and how do we do it? Acad Med 2010; 85:63–7. - PubMed
    1. Infectious Diseases Society of America. Advocacy bulletin. Available at: http://cqrcengage.com/idsociety/app/document/31917218?7. Accessed 8 August 2019.
    1. Infectious Diseases Society of America. IDSA board member describes AMR challenges, answers in congressional testimony. Available at: https://www.idsociety.org/news--publications-new/articles/2019/idsa-boar.... Accessed 27 July 2019.
    1. US House Committee on Oversight and Reform. HIV prevention drug: billions in corporate profits after millions in taxpayer investments. May 16, 2019. Testimony of Rochelle Walensky, MD, MPH. Available at: https://oversight.house.gov/legislation/hearings/hiv-prevention-drug-bil.... Accessed 27 July 2019.
    1. Infectious Diseases Society of America. Testimony of the Infectious Diseases Society of America’s (IDSA)and the Pediatric Infectious Diseases Society (PIDS). Available at: https://www.idsociety.org/globalassets/idsa/policy--advocacy/current_top.... Accessed 8 August 2019.

Publication types